Roche's Elevidys shows sustained benefits in DMD study
Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained ...
Roche's Muscle-Wasting Treatment Shows Positive Results in Late-Stage Trial
Late-stage trial data for Roche's drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.
BioSpace9h
5 DMD Candidates to Watch in 2025
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
BioSpace9h
Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Personalized therapy for rare genetic diseases: Patient-derived organoids offer new hope
Children's Mercy Kansas City has achieved a significant advancement toward the treatment of rare genetic diseases through the ...